GISAID operates under the principles of equal treatment of all users

Recent audits into the use of data feeds revealed irregularities and identified individuals who have violated their agreed terms.  Some of them were found to have considerably encroached on the rights of GISAID’s data contributors, which resulted in the termination of their data feed. Unfortunately, some individuals have created confusion by spreading disinformation in various forums. read more

Review of data-related complaints involving fraudulent activities

In recent months, GISAID has become aware that a small group of its users have violated the terms of their access Agreement and misused the data shared via GISAID.  Among them are individuals that received GISAID support to operate their own “dashboard” to display aggregate data, but have abused the GISAID data sharing process in violation of the rights inherent to the owners of that data.

April 13th Statement from GISAID

Since our last update, pathogen data sharing has continued to be a prominent topic of discussion as experts and non-experts voice their opinions, including about GISAID itself. Because of the ongoing spotlight and risk of confusion, we’ve shared some useful information

Here we address Dispute resolution between data users and data contributors, Contributions and funding, Governance, and Privacy of individuals,

GISAID comments on the speculations surrounding data availability

Recent discussions surrounding early hCoV-19 sequence data associated with a manuscript submitted by the researchers at the China CDC have been clouded by speculation regarding the status of the data. Here we clarify the current status of that data, and take this opportunity to reiterate the general data sharing policies at GISAID.

Routine updates to improve data in GISAID

GISAID is committed to near-instant processing and release of genome and metadata to ensure its platform continues to make emerging outbreak information accessible at unprecedented speeds and scale. From time to time, laboratories will increase the speed with which they generate data and submit to GISAID, for instance when new Variants of Interest or Variants of Concern are designated by the WHO. With this increased speed, the need to check for errors in genomic sequence data or metadata also increases. 

GISAID EpiCoV™ data quality control procedures and B.1.621 (Mu) monitoring

In late July 2021, GISAID confirmed with public health authorities its procedures for the quality control of gaps in genomic sequences that cause frameshifts and other genomic changes. Social media discussions mistakenly suggested B.1.621 (Mu) genome sequences could have been kept from release due to a 4nt deletion in ORF3A that results in a premature stop codon.

Clade and lineage nomenclature aids in genomic epidemiology of active hCoV-19 viruses

Due to the naturally expanding phylogenetic diversity of hCoV-19 viruses in late February 2020, GISAID named for consistent reporting larger clades, based on marker mutations within 6 high-level phylogenetic groupings from the early split of S and L, to the further evolution of L into V and G and later of G into GH, GRY (Alpha) and GK (Delta).  

New swine flu enters the watchlist

Virus surveillance in animals is an important aspect of pandemic preparedness to know what is out there and could cause zoonotic infections (jumps from animals to humans) or even represent pandemic threats. Colleagues have concluded a surveillance study in pigs and identified a new reassortant H1N1 swine flu that shows the minimal characteristics for a virus with pandemic potential.

Here are some important facts to consider:

Discussion on different types or clades of the hCoV-19 virus and their origin

As the outbreak evolves over time and more data becomes available, several colleagues have analyzed and proposed different "types" of the virus and their origin. Depending on choice of definitions one can classify the circulating virus strains into a different number of clades based on genetic variants. These are part of the natural evolution of the virus currently not known to be associated with any differences in virulence. 

GISAID Comments on the Implications of Access and Benefit- Sharing (ABS) Regimes on Global Health and Biomedical Research

The Global Initiative on Sharing All Influenza Data responds to the invitation by the U.S. Department of State (DOS) and comments on the effects of the Nagoya Protocol and other ABS implementation on public health systems, and emphasizes the collective global benefit of robust influenza virus surveillance which is achieved in part through the sharing of all influenza GSD in a timely manner. read more